MAMustafa Araz

Mustafa Araz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mustafa Araz has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Successful treatment with rituximab of a type 2 diabetes patient with antibody-mediated insulin resistance syndrome: A case report

    by Ramazan Çakmak, Sakin Tekin, Hülya Hacişahinoğullari, Ümmü Mutlu, Özge Telci Çaklili, Vefa Seferova Nasibopva, Ayşe Merve Ok, Göktuğ Saribeyliler, Mustafa Araz, Gülşah Yenidünya Yalin, et al.

    Rationale: Insulin antibody-mediated insulin resistance is a rare autoimmune mechanism that can cause severe hyperglycemia. Patient concerns: A 52-year-old male patient was admitted to our hospital with complaints of polydipsia, polyuria, and weight loss (8 kg in 6 months). He was diagnosed with type 2 diabetes mellitus at age 33. Diagnoses: Type 2 diabetes mellitus with antibody-mediated insulin resistance syndrome. Interventions: Rituximab infusion in a 500 mg dose was given 2 times in a 2-week interval. Outcomes: A significant response was achieved 1 month later with fasting plasma glucose: 120 mg/dL (6.7 mmol/L), glycosylated hemoglobin A1c: 7.6% (59.6 mmol/mol), and anti-insulin antibodies: 0.001 U/mL. Clinically improved response persisted for about 6 months. Lessons: Clinicians should be aware of the antibody-mediated insulin resistance, recognize suggestive signs and symptoms, pursue appropriate diagnostic evaluation, and treatment approach.


  • Frequency of silent myocardial ischemia in type 2 diabetic patients and the relation with poor glycemic control

    by M. Araz, Z. Celen, I. Akdemir, V. Okan

    The aim of the study was to investigate the frequency of silent myocardial ischemia in type 2 diabetic patients without any clinical or laboratory findings of myocardial ischemia and to examine the related factors for silent myocardial ischemia. A total of 116 type 2 diabetic patients (82 women) with a disease duration of 5–20 years were included in the study. All patients underwent stress and resting myocardial perfusion single-photon emission computed tomographic (SPECT) study with 99mTc-MIBI. Coronary angiography was performed in patients with ischemia established at myocardial perfusion SPECT. Ischemia was determined in 18 (15.5%) patients by myocardial perfusion SPECT. Coronary angiography performed in 17 of these patients confirmed coronary stenosis >50% in 11 patients. Thus, the prevalence of silent myocardial ischemia was 9.6%. Significant relations were found between silent myocardial ischemia and male sex, high HbA1C level and retinopathy. Type 2 diabetic patients (especially men) with poorly controlled diabetes mellitus or retinopathy should be screened for silent myocardial ischemia.


  • Angiotensin-converting enzyme gene polymorphism and coronary heart disease in Turkish type 2 diabetic patients

    by Mustafa Araz, Sükrü Aynacioglu, Vahap Okan, Ilyas Akdemir, Sebnem Aktaran

    It has been suggested that the insertion (I)/deletion (D) polymorphism of the angiotensin-converting enzyme (ACE) may be associated with atherosclerosis. The aim of the study was to examine the association between ACE gene polymorphism and coronary heart disease in Turkish type 2 diabetic patients. A total of 152 (97 female, 55 male) type 2 diabetic patients were included into the study. All patients underwent myocardial perfusion scintigraphic examination and forty-five of them with a perfusion defect underwent coronary angiography.Thirty-eight patients with a coronary stenosis of more than 50% on coronary angiography were considered as having coronary heart disease. The I/D polymorphism was determined by polymerase chain reaction. There was no statistically significant difference in genotypic and allelic frequencies of the ACE I/D polymorphism among patients with and without coronary heart disease (DD:ID:II (%), 32:58:11 and 39:44:17, respectively). ACE gene polymorphism is not a significant parameter to determine coronary heart disease in Turkish type 2 diabetic patients.


  • ANGIOTENSIN CONVERTING ENZYME GENE POLYMORPHISM AND GLOMERULAR FILTRATION RATE CHANGES IN TYPE 2 DIABETIC PATIENTS

    by M Araz, V Okan, Z Celen, S Aynacioglu

    It has been suggested that an insertion/deletion (I/D) polymorphism in intron 16 of the angiotensin-converting enzyme (ACE) gene may be associated with diabetic nephropathy The aim of this study was to investigate whether an association exists between ACE I/D polymorphism and glomerular filtration rate (GFR) in type 2 diabetes mellitus. A total of 128 type 2 diabetic patients were included in the study with the following ACE genotype distribution: DD 40, ID 58,11 30. I/D polymorphism was determined by polymerase chain reaction (PCR). Mean GFR was not statistically different according to ACE genotype (DD: 89.9 +/- 28.1 ml/min, ID: 99.5 +/- 25.1 ml/min, II: 96.6 +/- 19.6 ml/min). There was no significant difference in genotype distribution in normo-, micro- and macroalbuminuric patients (DD:ID:II [%], normo- 35:46:19, micro-28:55:17, macro- 31:55:14). ACE I/D polymorphism does not seem to be associated with GFR in type 2 diabetic patients.


  • INCREASED FREQUENCY OF HCV BUT NOT HBV INFECTION IN TYPE 2 DIABETIC PATIENTS IN TURKEY

    by V Okan, M Araz, S Aktaran, T Karsligil, I Meram, Z Bayraktaroglu, F Demirci

    The aim of this study was to investigate the prevalence of hepatitis B and hepatitis C virus infections in type 2 diabetic patients in Gaziantep, Turkey. Six hundred and ninety-two type 2 diabetic patients and 1014 healthy blood donors were included in the study. No significant difference was found between type 2 diabetic patients and the control group for seropositivity of HBsAg (5.3% vs 5.1%, p>0.05). In contrast, anti-HCV was significantly more frequent in type 2 diabetic patients (7.5% vs 0.1%, p>0.0001). We found no significant difference for HBsAg seropositivity between type 2 diabetic patients with a disease duration of 12 months or less, but anti-HCV seropositivity was significantly more frequent in diabetic patients with a longer disease duration (p<0.05). We suggest that HCV infection is not a trigger factor for type 2 diabetes mellitus but is frequently associated with it.


  • Angiotensin-converting enzyme gene polymorphism and microvascular complications in Turkish type 2 diabetic patients

    by Mustafa Araz, Necat Yilmaz, Kivanc Güngör, Vahap Okan, Yalcin Kepekci, A. Sükrü Aynacioglu


  • Open Access

    Association Between Polymorphism of the Angiotensin I Converting Enzyme Gene and Hypertension in Turkish Type II Diabetic Patients

    by Mustafa Araz, Sükrü Aynacioglu, Sebnem Aktaran, Belgin Alasehirli, Vahap Okan

    It has been suggested that an insertion/deletion (I/D) polymorphism in intron 16 of the angiotensin converting enzyme (ACE) gene may be associated with essential hypertension. The aim of this study was to examine the association between ACE I/D polymorphism with blood pressure level and hypertension status in Turkish type 2 diabetic subjects. Hundred and seven hypertensive (78 female, 29 male) and 132 normotensive type 2 diabetic subjects (73 female, 59 male) and 138 sex and age matched control subjects (87 female, 51 male) without diabetes and hypertension were included into the study. The I/D polymorphism was determined by polymerase chain reaction (PCR). There were no statistically difference in genotypic and allelic frequencies of the ACE I/D polymorphism between the hypertensive and normotensive diabetic patients and control subjects. Also no significant differences was detected in systolic and diastolic blood pressure among three different genotypes. ACE I/D polymorphism does not seem to play an important role in the development of hypertension in Turkish type 2 diabetic subjects, but prospective studies may show an association between ACE gene polymorphism and the development of hypertension in diabetic subjects.